Sarepta Therapeutics (SRPT) Weakness Should Be Bought - Nomura/Instinet
August 8, 2019 2:02 PM
Nomura/Instinet analyst Christopher Marai reiterated a Buy rating and $230.00 price target on Sarepta Therapeutics (NASDAQ: SRPT) with shares halted ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
